PEOPLE - DiaSys makes appointment:
This article was originally published in Clinica
Diagnostics firm DiaSys (Waterbury, Connecticut) has formed a medical advisory board to assist with R&D projects related to expanding its product lines. Dr John Chen, co-founder of IVD firms BioCheck, Rapid Diagnostics, Medix Biotech (acquired by Genzyme in 1992) and Pacific Biotech (acquired by Eli Lilly), has been appointed to the board. He is joined by: Lynne Garcia, director of LSG Associates, a provider of diagnostic medical parasitology and healthcare administration; Anthony Moody, formerly head biomedical scientist at the Hospital of Tropical Diseases; and Dr Berry Schumann, who is currently medical director for Diagnostic Oncology CRO, a position he has held since 2001.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.